Topic: endocrine disorders
Horizon presented new data for its eye drug teprotumumab that dig deeper into how fast the drug works and how it stacks up against eye surgery.
Tiburio Therapeutics starts life with $31 million in series A funding and a pair of clinical-stage compounds licensed from Ipsen.
Just months after Crinetics picked up $63.5 million in its series B, the GPCR specialist is filing to raise up to $86 million in its IPO.
Perceptive leads a Series B round that will fund Crinetics' CRN00808 candidate through proof-of-concept studies.